English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/234713
logo share SHARE   Add this article to your Mendeley library MendeleyBASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:


Bimodal Therapeutic Agents Against Glioblastoma, One of the Most Lethal Forms of Cancer

AuthorsCouto, Marcos; Alamón, Catalina; Nievas, Susana; Perona, Marina; Dagrosa, María Alejandra; Teixidor, Francesc ; Cabral, Pablo; Viñas, Clara ; Cerecetto, Hugo
KeywordsBimodal therapy
Boron neutron capture therapy
Issue Date11-Nov-2020
CitationChemistry - a European Journal 26(63): 14335-14340 (2020)
AbstractAbout 95 % of people diagnosed with glioblastoma die within five years. Glioblastoma is the most aggressive central nervous system tumour. It is necessary to make progress in the glioblastoma treatment so that advanced chemotherapy drugs or radiation therapy or, ideally, two‐in‐one hybrid systems should be implemented. Tyrosine kinase receptors–inhibitors and boron neutron capture therapy (BNCT), together, could provide a therapeutic strategy. In this work, sunitinib decorated‐carborane hybrids were prepared and biologically evaluated identifying excellent antitumoral‐ and BNCT‐agents. One of the selected hybrids was studied against glioma‐cells and found to be 4 times more cytotoxic than sunitinib and 1.7 times more effective than 10B‐boronophenylalanine fructose complex when the cells were irradiated with neutrons.
Publisher version (URL)http://dx.doi.org/10.1002/chem.202002963
Appears in Collections:(ICMAB) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
Show full item record
Review this work

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.